Inter partes review

Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review

Retrieved on: 
Wednesday, March 27, 2024
Professional Services, Health, Neurology, Legal, Finance, General Health, Pharmaceutical, PGR, Plasma, Medication, Patent, Patient, Ganaxolone, PTAB, IPR, Marinus, Pharmacology, Inter partes review, Patent office, Therapy, Epilepsy, Status epilepticus, Pharmaceutical industry

This challenge relates to a Marinus patent for the use of ganaxolone in treating status epilepticus (SE) and refractory status epilepticus (RSE).

Key Points: 
  • This challenge relates to a Marinus patent for the use of ganaxolone in treating status epilepticus (SE) and refractory status epilepticus (RSE).
  • “Over the past two decades, Marinus has invested more than $100 million into our ganaxolone development programs in SE,” stated Dr. Scott Braunstein, Chairman and CEO of Marinus.
  • We believe this Ovid challenge is without merit and is an unfortunate distraction to the important work we do at Marinus.
  • In response to Marinus’ request for PGR, Ovid abandoned 23 of the 31 claims in its patent.

Vizgen Announces Denial of 10x Genomics’ Petition for Inter Partes Review of Vizgen-Licensed Patent Currently Asserted Against 10x’s Xenium Platform

Retrieved on: 
Wednesday, March 13, 2024
Medical Devices, Infectious Diseases, Neurology, Genetics, Health Technology, Biometrics, Biotechnology, Pharmaceutical, Health, Oncology, Genomics, Science, Patent, District court, PTAB, IPR, Harvard University, Invention, Inter partes review

This is the latest in a series of rulings against 10x in its aggressive attempts to weaponize patents to dominate the field through baseless litigation.

Key Points: 
  • This is the latest in a series of rulings against 10x in its aggressive attempts to weaponize patents to dominate the field through baseless litigation.
  • 22-595-MFK, the parallel case in the U.S. District Court for the District of Delaware, Vizgen has asserted a number of counterclaims including the assertion that the Xenium platform infringes certain claims of the ‘303 Patent.
  • It is very encouraging to see our patent prevail on the basis of its technical and scientific contributions to the field.
  • We believe the PTAB’s decision underscores the importance and value of Vizgen’s inventions,” said Terry Lo, CEO of Vizgen.

Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara®

Retrieved on: 
Thursday, February 29, 2024
Psoriatic arthritis, Ulcerative colitis, Crohn's disease, Psoriasis, Ustekinumab, Trademark, FDA, Patent, Johnson & Johnson, BLA, Inflammation, IPR, PTAB, Inter partes review, Patient, Science, BBL, Pharmaceutical industry

The agreement licenses the Company to launch in the United States, in February 2025, once approved by the U.S. FDA.

Key Points: 
  • The agreement licenses the Company to launch in the United States, in February 2025, once approved by the U.S. FDA.
  • The U.S. FDA has accepted the Company's Biologics License Application (BLA) for Bmab 1200 (bUstekinumab) for review under the 351(k) pathway.
  • Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd, said: "This settlement agreement reflects our commitment and focus on science and innovation.
  • As a fully integrated biosimilars company, Biocon Biologics is committed to expanding access to life-changing treatments with our broad portfolio of products."

U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)

Retrieved on: 
Wednesday, December 20, 2023
Drug, Food, UTHR, PAH, FDA, PDUFA, Inter partes review, Patent, NDA, IPR, United Therapeutics, Patient, Orthostatic hypertension, PTAB, Pulmonary hypertension, District court

10,716,793 (‘793 Patent) to be unpatentable due to the existence of prior art cited by Liquidia in inter partes review (IPR) proceedings.

Key Points: 
  • 10,716,793 (‘793 Patent) to be unpatentable due to the existence of prior art cited by Liquidia in inter partes review (IPR) proceedings.
  • Roger Jeffs, Chief Executive Officer of Liquidia, stated: “We are thrilled with the court’s swift decision.
  • We now have rulings from the Federal Circuit confirming that YUTREPIA does not infringe any valid claim in any of the three patents that were initially asserted by United Therapeutics.
  • The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of January 24, 2024, for the PH-ILD indication.

DSS Inc. Wins Patent Dispute with Nichia Corporation

Retrieved on: 
Tuesday, November 14, 2023
NYSE, Electronics, Inter partes review, LED, Light-emitting diode, DSS, IPR, CAFC, Patent, Court

NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) announced today that, in a unan​i​mous decision, the Court of Appeals for the Federal Circuit (CAFC) rejected Nichia Corp.'s challenge to U.S. Patent No.

Key Points: 
  • NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) announced today that, in a unan​i​mous decision, the Court of Appeals for the Federal Circuit (CAFC) rejected Nichia Corp.'s challenge to U.S. Patent No.
  • 6,879,040 (the ‘040 Patent).
  • The CAFC appeal mounted by Nichia Corp., a Japanese electronics company, asserted that a 2021 Inter Partes Review (IPR) decision by the USPTO Patent Trial and Appeal Board declaring the ‘040 Patent to be valid should be overturned.
  • The arguments put forth by Nichia were soundly defeated by the Board in 2021 and now, again, by the CAFC.

Miller Barondess Expands IP Litigation Practice

Retrieved on: 
Wednesday, November 1, 2023
Professional Services, Legal, Patent Law, Insurance, University of Colorado Law School, Sport, Patent, Arizona State University, Theft, Government, Face, Inter partes review, Intellectual property, United States Court of Appeals for the Federal Circuit, Multimedia, Patent office, LLP, Partnership, Kirkland & Ellis, Sandra, University, Health, Lawyer, 3D printing, IP

Miller Barondess, LLP adds top patent and trade secret litigator Ben Herbert to its partnership, continuing the expansion of the firm's Intellectual Property practice.

Key Points: 
  • Miller Barondess, LLP adds top patent and trade secret litigator Ben Herbert to its partnership, continuing the expansion of the firm's Intellectual Property practice.
  • Adding his patent expertise to the IP team further enhances the firm's already robust IP practice and solidifies its position as a powerhouse in IP litigation.
  • "We are very pleased to have Ben working with us as the firm continues to grow," said Skip Miller, a founding partner of Miller Barondess.
  • Miller Barondess is a Los Angeles-based firm specializing in litigation, trial, and appellate work in California and around the country.

Osha Bergman Watanabe & Burton LLP: Jury Awards $12.8 Million to WOW Tech in IP Dispute

Retrieved on: 
Monday, September 18, 2023
Patent, IPR, United States Court of Appeals for the Federal Circuit, OSHA, EIS, Woman, Walker Process Equipment, Inc. v. Food Machinery & Chemical Corp., Lawyer, Inter partes review, Patent Trial and Appeal Board, District court, OBWB, Lanham Act, Ridesharing, Cole

HOUSTON, Sept. 18, 2023 /PRNewswire/ -- A four-year legal battle over sexual stimulation device technology for women has led to a federal-court jury verdict of $12.8 million for a group of businesses collectively known as WOW Tech, its lawyers at Osha Bergman Watanabe & Burton LLP (OBWB) said today.

Key Points: 
  • HOUSTON, Sept. 18, 2023 /PRNewswire/ -- A four-year legal battle over sexual stimulation device technology for women has led to a federal-court jury verdict of $12.8 million for a group of businesses collectively known as WOW Tech, its lawyers at Osha Bergman Watanabe & Burton LLP (OBWB) said today.
  • The jury also confirmed the validity of all five of the WOW Tech group's patents and entered findings of willful patent infringement against EIS, Inc, EIS GmbH, Triple A Marketing GmbH, and Triple A Import GmbH.
  • The WOW Tech group is represented by lead counsel Tammy Terry , and OBWB attorneys Lisa Margonis, Califf T. Cooper, and Gopal Rao Gannamraj.
  • Osha Bergman Watanabe & Burton LLP Partner Tammy Terry said, "We're grateful for the jury's decisive ruling in favor of the WOW Tech group.

Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 10, 2023
Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Student Borrower Protection Center, Partnership, United States Court of Appeals for the Federal Circuit, Inter partes review, The Orange Book, PAH, CAFC, Calendar, Treprostinil, NDA, PTAB, Sale, Certification, Security, Orange Book, Patent Trial and Appeal Board, District court, Patent, Patient, United States district court, Research, FDA, Pulmonary hypertension, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, UTHR, Cryptocurrency, Pharmaceutical industry, United Therapeutics

MORRISVILLE, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • MORRISVILLE, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the second quarter ended June 30, 2023.
  • ET to discuss the financial results and provide a corporate update.
  • Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “This quarter saw Liquidia significantly advance our mission to become the leading inhaled treprostinil provider for pulmonary hypertension patients.
  • Briefing in the appeal should be completed in fourth quarter 2023 and oral arguments will be heard on the next available date in the oral argument calendar, expected to be late fourth quarter 2023 to early 2024.

VoIP-Pal Receives Favorable IPR Institution Decisions

Retrieved on: 
Tuesday, August 1, 2023
Patent, IPR, Intellectual property, PTAB, Patent Trial and Appeal Board, Verizon Communications, T-Mobile, Inter partes review, Mobile phone, Pharmaceutical industry, Amazon

The PTAB has also denied institution of T-Mobile’s corresponding IPR petition.

Key Points: 
  • The PTAB has also denied institution of T-Mobile’s corresponding IPR petition.
  • As a result of these events, all IPR petitions against the Company have now been terminated.
  • “We are very happy to be finished with all the IPR challenges to our patents,” said Emil Malak, CEO of VoIP-Pal.
  • “It is a very significant accomplishment for us to have survived 28 IPR challenges over the past seven years without losing a single claim.

RideCo Receives Favorable Pre-Trial Rulings in Patent Litigation with Via Transportation

Retrieved on: 
Wednesday, July 26, 2023
Via Transportation, Patent Trial and Appeal Board, Court, Inter partes review, LOS, Patent, Transport, Hearing, United States district court, Generic drug, Via

RideCo secures court wins on several important issues in advance of trial in its patent litigation with Via Transportation ("Via").

Key Points: 
  • RideCo secures court wins on several important issues in advance of trial in its patent litigation with Via Transportation ("Via").
  • Ruling from the bench, the Court denied each of Via's motions heard by the Court.
  • We are glad that the Court took a careful look at these motions, and we are pleased with the favorable rulings.
  • RideCo is well-positioned for trial where we will seek to stop Via's ongoing infringement through an injunction," said Prem Gururajan, CEO of RideCo.